Clinical Trial Update: VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update indicating recruitment for a Phase 2/3 study evaluating rivaroxaban to prevent venous thromboembolism in patients with genitourinary can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genitourinary Cancer
• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Venous Thromboembolism, Urologic Cancer | Phase 2, Phase 3 | Status: RECRUITING